Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Eisenstadt – page 59

861 clinical trials in Eisenstadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Eisenstadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Eisenstadt

Open in trial search

Study of Osimertinib and Chemotherapy for Patients with EGFR Mutation Positive Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Betula Pollen Extract
  • Sponsor:Stallergenes

Uveal melanoma+2

Not recruiting

Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Novartis Pharma AG

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Medica Scientia Innovation Research S.L.

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Eisenstadt

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure and pulmonary hypertension, specifically addressing conditions related to left heart disease. These trials aim to evaluate new therapeutic approaches for patients with complex cardiovascular conditions.

  • Heart Failure Management
  • Pulmonary Vascular Disease
  • Left Heart Disease Complications

The research examines treatment effectiveness in patients with WHO Group 2 pulmonary hypertension, exploring potential improvements in pulmonary vascular resistance over a 24-week period.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.